Search research articles
Contact Us
Filters
Showing results (61-70 of 155) with videos related to
Page
of 16
Sort By:
The Journal of Urology
|
November 13, 2012
Prospective, randomized, double-blind, vehicle controlled, multicenter phase IIb clinical trial of the pore forming protein PRX302 for targeted treatment of symptomatic benign prostatic hyperplasia
Mostafa M Elhilali, Peter Pommerville, Richard C Yocum, et al.
Journal of Medicinal Chemistry
|
April 15, 2005
Applying linear interaction energy method for rational design of noncompetitive allosteric inhibitors of the sarco- and endoplasmic reticulum calcium-ATPase
Pratap Singh, Anastasiah M Mhaka, Soren B Christensen, et al.
The Prostate
|
April 17, 2018
PSA-alpha-2-macroglobulin complex is enzymatically active in the serum of patients with advanced prostate cancer and can degrade circulating peptide hormones
Maya B Kostova, William Nathaniel Brennen, David Lopez, et al.
The Prostate
|
March 12, 2011
Enzymatically active prostate-specific antigen promotes growth of human prostate cancers
Simon A Williams, Christine A Jelinek, Ivan Litvinov, et al.
Stem Cells Translational Medicine
|
August 3, 2018
Concise Review: Mesenchymal Stem Cell-Based Drug Delivery: The Good, the Bad, the Ugly, and the Promise
Timothy E G Krueger, Daniel L J Thorek, Samuel R Denmeade, et al.
Cancer Biology & Therapy
|
March 27, 2004
Use of methotrexate-based peptide substrates to characterize the substrate specificity of prostate-specific membrane antigen (PSMA)
Annastasiah Mhaka, Alyssa M Gady, D Marc Rosen, et al.
The Prostate
|
July 24, 2014
Pharmacokinetics and toxicology of a fibroblast activation protein (FAP)-activated prodrug in murine xenograft models of human cancer
W Nathaniel Brennen, D Marc Rosen, Alcides Chaux, et al.
European Urology Open Science
|
June 9, 2022
Clinical Efficacy of Bipolar Androgen Therapy in Men with Metastatic Castration-Resistant Prostate Cancer and Combined Tumor-Suppressor Loss
Mark C Markowski, Hao Wang, Angelo M De Marzo, et al.
Journal of the National Cancer Institute
|
March 8, 2007
A prostate-specific antigen-activated channel-forming toxin as therapy for prostatic disease
Simon A Williams, Rosemina F Merchant, Elizabeth Garrett-Mayer, et al.
Proteins
|
September 27, 2007
Mechanistic insights into the inhibition of prostate specific antigen by beta-lactam class compounds
Pratap Singh, Simon A Williams, Meha H Shah, et al.
Page
of 16
Search research articles
Search
Showing results (61-70 of 155) with videos related to
Sort By:
Page
of 16
The Journal of Urology
|
November 13, 2012
Prospective, randomized, double-blind, vehicle controlled, multicenter phase IIb clinical trial of the pore forming protein PRX302 for targeted treatment of symptomatic benign prostatic hyperplasia
Mostafa M Elhilali, Peter Pommerville, Richard C Yocum, et al.
Journal of Medicinal Chemistry
|
April 15, 2005
Applying linear interaction energy method for rational design of noncompetitive allosteric inhibitors of the sarco- and endoplasmic reticulum calcium-ATPase
Pratap Singh, Anastasiah M Mhaka, Soren B Christensen, et al.
The Prostate
|
April 17, 2018
PSA-alpha-2-macroglobulin complex is enzymatically active in the serum of patients with advanced prostate cancer and can degrade circulating peptide hormones
Maya B Kostova, William Nathaniel Brennen, David Lopez, et al.
The Prostate
|
March 12, 2011
Enzymatically active prostate-specific antigen promotes growth of human prostate cancers
Simon A Williams, Christine A Jelinek, Ivan Litvinov, et al.
Stem Cells Translational Medicine
|
August 3, 2018
Concise Review: Mesenchymal Stem Cell-Based Drug Delivery: The Good, the Bad, the Ugly, and the Promise
Timothy E G Krueger, Daniel L J Thorek, Samuel R Denmeade, et al.
Cancer Biology & Therapy
|
March 27, 2004
Use of methotrexate-based peptide substrates to characterize the substrate specificity of prostate-specific membrane antigen (PSMA)
Annastasiah Mhaka, Alyssa M Gady, D Marc Rosen, et al.
The Prostate
|
July 24, 2014
Pharmacokinetics and toxicology of a fibroblast activation protein (FAP)-activated prodrug in murine xenograft models of human cancer
W Nathaniel Brennen, D Marc Rosen, Alcides Chaux, et al.
European Urology Open Science
|
June 9, 2022
Clinical Efficacy of Bipolar Androgen Therapy in Men with Metastatic Castration-Resistant Prostate Cancer and Combined Tumor-Suppressor Loss
Mark C Markowski, Hao Wang, Angelo M De Marzo, et al.
Journal of the National Cancer Institute
|
March 8, 2007
A prostate-specific antigen-activated channel-forming toxin as therapy for prostatic disease
Simon A Williams, Rosemina F Merchant, Elizabeth Garrett-Mayer, et al.
Proteins
|
September 27, 2007
Mechanistic insights into the inhibition of prostate specific antigen by beta-lactam class compounds
Pratap Singh, Simon A Williams, Meha H Shah, et al.
Page
of 16